RNAi: A REVOLUTION IN BIOLOGY BUILT ON NOBEL PRIZE-WINNING RESEARCH
RNA interference (RNAi) is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development. The 2006 Nobel Prize for Physiology or Medicine, awarded to Craig Mello and Andrew Fire, recognised the importance of RNAi as a major scientific discovery.
Learn more about RNAi
Learn more about our research, programs, company, culture, patient stories and more.
OUR FOCUS
Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall under 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Our products approved for patients in the European Union treat hereditary ATTR (hATTR) amyloidosis with polyneuropathy, acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1). Our therapeutic product candidates in late-stage (Phase 2 – Phase 3) development focus on hereditary ATTR (hATTR) amyloidosis, haemophilia and rare bleeding disorders, hypercholesterolaemia and complement-mediated diseases. We have a number of early-stage programmes in development.
JOIN OUR TEAM
As we pursue our goal of becoming a commercial organization that can independently deliver medicines to patients, we are seeking individuals with diverse skills, experiences, and backgrounds to help us build a world-class team. We are based in Cambridge, USA, with offices in Zug, Switzerland, and Maidenhead, UK, but we are also hiring throughout Europe.
CONTACT US
Alnylam UK Ltd.
Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA
For medical information, clinical trial questions or to report an adverse event or product complaint:
Toll: +353 818 882213
Toll-free: 1800 924 260 (also hidden caller ID)
LEARN MORE ABOUT ALNYLAM
In-depth information about our science, our pipeline, resources for medical professionals and patients, and the latest news about Alnylam.
Date of prep: July 2023
Corp-IRL-00004
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site